AtaiBeckley Inc.
ATAIDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002081043
AtaiBeckley Inc. was delisted in 2026; its insiders filed their last Form 4 on Sep 11, 2026; 242 institutions reported holding it in 13F filings for Q2 2026, worth $710.7M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by AtaiBeckley Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $496.0K in total
- Insiders trading
- 1
- Net value
- −$496.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for AtaiBeckley Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kochendoerfer Gerd | Chief Operating Officer | 0 | Sep 11, 2026 | 3 |
| Craig Kevin James | Chief Medical Officer | 0 | Sep 11, 2026 | 5 |
| Johnson Anne Nagengast | Chief Accounting Officer | 0 | Sep 11, 2026 | 2 |
| Barrett Christopher Ryan Cave | See remarks | 0 | Sep 11, 2026 | 3 |
| Short Glenn Frank | Chief Scientific Officer | 0 | Sep 11, 2026 | 2 |
| Faerm Michael E. | Chief Financial Officer | – | Sep 11, 2026 | 2 |
| Fischer Laurent | Director | – | Sep 11, 2026 | 2 |
| Hoffman John Francis | Director | – | Sep 11, 2026 | 2 |
| Kalali Amir H | Director | 0 | Sep 11, 2026 | 2 |
| Smiley Andrea Heslin | Director | 0 | Sep 11, 2026 | 2 |
| Braunstein Scott | Director | – | Sep 11, 2026 | 3 |
| Rao Srinivas | See remarks | 0Indirect | Sep 11, 2026 | 2 |
| Hershberg Robert | Director | 100,000 | Sep 11, 2026 | 4 |
| Johnson Sabrina Martucci | Director | – | Sep 11, 2026 | 2 |
| Apeiron Investment Group Ltd. | 10% Owner | 0Indirect | Sep 11, 2026 | 3 |
| Angermayer Christian | Director, 10% Owner | 0Indirect | Sep 11, 2026 | 4 |
| Feilding-Mellen Cosmo | Director | 7,663,396 | Jan 6, 2026 | 3 |
| Kirpekar Sahil | Chief Business Officer | 115,636 | Mar 24, 2025 | 0 |
| Brand Florian | See Remarks | 328,697 | Oct 4, 2024 | 0 |
| Auerbach Michael | Director | 0Indirect | Jun 14, 2024 | 0 |
| Camm Jason | Director | – | May 25, 2023 | 0 |
| Gutierrez-Esteinou Rolando | Chief Medical Officer | – | Mar 16, 2023 | 0 |
| Bardin Stephen | Chief Financial Officer | – | Mar 16, 2023 | 0 |
| de Rosnay Alexis | Director | – | May 27, 2022 | 0 |
| Weaver Gregory L | Chief Financial Officer | – | Mar 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 (view filing)5:30 PM ET | Jul 7 | 2 days | Hershberg RobertDirector | SSale | −100.0K | $4.96 | −$496.0K | −50.0%100.0K after | 10b5-1 |
| Jun 29, 2026 (view filing) | Jun 25 | 4 days | Craig Kevin JamesChief Medical Officer | SSale | −42.6K | $4.51 | −$192.0K | −83.5%8.44K after | 10b5-1 |
| Jun 29, 2026 (view filing) | Jun 26 | 3 days | Kochendoerfer GerdChief Operating Officer | SSale | −50.0K | $5.00 | −$250.0K | −100.0%0 after | 10b5-1 |
| Apr 22, 2026 (view filing) | Apr 20 | 2 days | Craig Kevin JamesChief Medical Officer | SSale | −42.6K | $5.00 | −$212.9K | −83.5%8.44K after | 10b5-1 |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Craig Kevin JamesChief Medical Officer | SSale | −100.0K | $3.55 | −$355.0K | −92.2%8.44K after | 10b5-1 |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Feilding-Mellen CosmoDirector | SSale | −39.6K | $3.90 | −$154.4K | −0.5%7.66M after | |
| Aug 18, 2025 (view filing)6:00 PM ET | Aug 14 | 4 days | Angermayer Christian and 1 otherDirector, 10% Owner | PPurchase | +8.68M | $2.19 | +$19.0M | +20.5%51.0M after | |
| Mar 24, 2025 (view filing)5:00 PM ET | Mar 24 | Same day | Angermayer Christian and 1 otherDirector, 10% Owner | PPurchase | +1.80M | $1.40 | +$2.52M | +4.4%42.4M after | |
| Mar 24, 2025 (view filing) | Mar 21 | 3 days | Kirpekar SahilChief Business Officer | SSale | −48.6K | $1.35 | −$65.6K | −29.6%115.6K after | |
| Mar 24, 2025 (view filing) | Mar 21 | 3 days | Craig Kevin JamesChief Medical Officer | SSale | −11.6K | $1.35 | −$15.6K | −57.8%8.44K after | |
| Mar 24, 2025 (view filing) | Mar 21 | 3 days | Rao SrinivasSee Remarks | SSale | −75.4K | $1.35 | −$101.8K | −26.2%212.9K after | |
| Mar 24, 2025 (view filing) | Mar 21 | 3 days | Johnson Anne NagengastChief Financial Officer | SSale | −33.5K | $1.35 | −$45.3K | −19.3%140.0K after | |
| Mar 24, 2025 (view filing) | Mar 21 | 3 days | Short Glenn FrankChief Scientific Officer | SSale | −13.2K | $1.35 | −$17.8K | −23.7%42.3K after | |
| Feb 19, 2025 (view filing)6:00 PM ET | Feb 14 | 5 days | Angermayer Christian and 1 otherDirector, 10% Owner | PPurchase | +10.8M | $2.10 | +$22.8M | +36.5%40.6M after | |
| May 20, 2024 (view filing) | May 16 | 4 days | Brand FlorianSee Remarks | SSale | −151.3K | $1.92 | −$290.5K | −31.5%328.7K after | |
| Apr 4, 2024 (view filing) | Apr 2 | 2 days | Johnson Anne NagengastChief Financial Officer | SSale | −27.4K | $1.85 | −$50.7K | −27.1%73.6K after | |
| Apr 4, 2024 (view filing) | Apr 2 | 2 days | Rao SrinivasSee Remarks | SSale | −61.6K | $1.85 | −$114.0K | −35.2%113.4K after | |
| Apr 4, 2024 (view filing) | Apr 2 | 2 days | Kirpekar SahilChief Business Officer | SSale | −35.8K | $1.85 | −$66.2K | −35.8%64.2K after | |
| Nov 20, 2023 (view filing) | Nov 16 | 4 days | Brand FlorianSee Remarks | PPurchase | +20.0K | $1.16 | +$23.2K | +18.2%130.0K after | |
| Sep 14, 2023 (view filing) | Sep 13 | 1 day | Brand FlorianSee Remarks | PPurchase | +40.0K | $1.45 | +$58.0K | +57.1%110.0K after | |
| Mar 30, 2023 (view filing) | Mar 29 | 1 day | Brand FlorianSee Remarks | PPurchase | +70.0K | $1.48 | +$103.6K | New position70.0K after | |
| Mar 29, 2023 (view filing)4:05 PM ET | Mar 29 | Same day | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +1.21M | $1.32 | +$1.60M | +3.9%32.1M after | |
| May 3, 2022 (view filing)4:16 PM ET | Apr 20-21 | 13 daysLate | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +136.4K | $5.02 | +$684.6K | +9.2%1.61M after | 2 lots |
| May 2, 2022 (view filing)4:15 PM ET | Apr 28-29 | 4 days | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +56.6K | $4.46 | +$252.5K | +3.2%1.80M after | 2 lots |
| Apr 28, 2022 (view filing)4:26 PM ET | Apr 26-27 | 2 days | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +66.0K | $4.67 | +$308.6K | +3.9%1.74M after | 2 lots |
| Apr 26, 2022 (view filing)4:15 PM ET | Apr 22-25 | 4 days | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +61.8K | $4.82 | +$297.8K | +3.8%1.68M after | 2 lots |
| Apr 20, 2022 (view filing)4:30 PM ET | Apr 18-19 | 2 days | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +119.6K | $5.12 | +$612.4K | +8.8%1.48M after | 2 lots |
| Apr 18, 2022 (view filing)4:15 PM ET | Apr 14 | 4 days | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +4.97K | $5.19 | +$25.8K | +0.4%1.36M after | |
| Apr 14, 2022 (view filing)4:15 PM ET | Apr 12 | 2 days | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +55.2K | $4.88 | +$269.6K | +4.3%1.35M after | |
| Apr 12, 2022 (view filing)4:30 PM ET | Apr 8-11 | 4 days | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +111.6K | $4.82 | +$538.2K | +9.4%1.30M after | 2 lots |
| Apr 7, 2022 (view filing)4:15 PM ET | Apr 6 | 1 day | Apeiron Investment Group Ltd. and 1 other10% Owner | PPurchase | +1.00M | $0.9598 | +$959.8K | –1.00M after | Derivative |